Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vamorolone - Santhera Pharmaceuticals

Next Previous
Drug Profile

Vamorolone - Santhera Pharmaceuticals

Alternative Names: AGAMREE; VB-15; VBP-15

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ReveraGen BioPharma
  • Developer KYE Pharmaceuticals; ReveraGen BioPharma; Santhera Pharmaceuticals; Sperogenix Therapeutics
  • Class Anti-inflammatories; Antianaemics; Antiasthmatics; Antifibrotics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnatrienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duchenne muscular dystrophy
  • Preclinical Unspecified
  • Discontinued Amyotrophic lateral sclerosis; Asthma; Brain cancer; Cystic fibrosis; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Sickle cell anaemia; Spinal muscular atrophy

Most Recent Events

  • 19 Aug 2025 Uniphar gains right to distribute Vamorolone for Duchenne muscular dystrophy (DMD) (In children, In adolescent, In adults, In elderly) in United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain
  • 13 Aug 2025 Santhera Pharmaceuticals and GEN Pharmaceuticals (Gen Ilac) enters into distribution agreement for Vamorolone (AGAMREE®) for Duchenne muscular dystrophy (DMD) (In children, In adolescent, In adults, In elderly) in Turkey
  • 29 Apr 2025 Sperogenix plans to launch Vamorolone for Duchenne muscular dystrophy in mid-2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top